John Schieszer, MA

In patients with recurrent oligometastatic hormone-sensitive prostate cancer, stereotactic ablative radiation therapy decreased the risk of disease progression compared with observation alone, a phase 2 study found.

DNA sequencing in men with metastatic castration-sensitive prostate cancer revealed alterations in certain signaling pathways that predict worse overall survival and shorter progression time to castration-resistant disease.